In the present study, we have investigated the anti-COVID-19 activity of Mortaparib and MortaparibPlus against three target proteins, namely ACE2, TMPRSS2, and Mpro using bioinformatics approaches and cell-based assays. This evidence concerns the gene ACE2 and COVID-19.